SEC Comment Letter 0000000000-23-012771 to SCYNEXIS INC (SCYX) (CIK 0001178253) (SCYX)

SCYNEXIS INC (SCYX) (CIK 0001178253)
Date: Nov. 21, 2023 · CIK: 0001178253 · Accession: 0000000000-23-012771

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-275520

Date

November 20, 2023

Author

Division of Corporation Finance

Form

UPLOAD

Company

SCYNEXIS INC (SCYX) (CIK 0001178253)

Letter

United States securities and exchange commission logo November 20, 2023 Dr. David Angulo Chief Executive Officer SCYNEXIS INC 1 Evertrust Plaza, 13th Floor Jersey City, NJ 07302-6548

Re: SCYNEXIS INC Registration Statement on Form S-3 Filed November 13, File No. 333-275520

Dear Dr. David Angulo:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy Polynice at 202-551-8707 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          November 20, 2023

       Dr. David Angulo
       Chief Executive Officer
       SCYNEXIS INC
       1 Evertrust Plaza, 13th Floor
       Jersey City, NJ 07302-6548

                                                        Re: SCYNEXIS INC
                                                            Registration
Statement on Form S-3
                                                            Filed November 13,
2023
                                                            File No. 333-275520

       Dear Dr. David Angulo:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Cindy
Polynice at 202-551-8707 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Matthew Hemington, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io